PALI Palisade Bio Inc.

FDA Catalyst Company
0.53
-0.02  -4%
Previous Close 0.56
Open 0.6
52 Week Low 0.4
52 Week High 4.57
Market Cap $9,050,602
Shares 18,233,479
Float 13,653,599
Enterprise Value $-1,076,977
Volume 173,943
Av. Daily Volume 1,996,850
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Ladenburg Thalmann Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/02/2022
Maxim Group Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/31/2021

Latest News

  1. Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022

    Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal adhesions

    CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the quarter ended March 31, 2022.

    Additionally, the Company provided a clinical program update for its lead asset in development, LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during…

    View Full Article
  2. CARLSBAD, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) (the "Company" or "Palisade Bio"), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55 per share.

    Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

    The closings of the sale of the securities in the financing is expected to occur on or about May 10, 2022, subject to the satisfaction of customary closing conditions…

    View Full Article
  3. NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study

    Newsoara to fully fund Phase 3 program in China

    Under the Co-Development Agreement, commencement of Phase 3 program in China will trigger milestone payment to Palisade Bio

    CARLSBAD, Calif. and SHANGHAI, China, May 05, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications and co-development partner Newsoara Biopharma Co. Ltd, today announced they have received clearance from the National Medical Products Administration (NMPA) in China to proceed with their…

    View Full Article
  4. CARLSBAD, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provided a business outlook and outlined its expected near-term pipeline advancements.

    "The positive data we have amassed continues to support our development strategy and provides us with confidence as we advance our lead program into a Phase 3 study this quarter. Each day that a patient remains in the hospital can cost upwards of approximately $2,400, representing a significant burden on the cost of healthcare. We believe, if approved, LB1148 will protect gastrointestinal integrity and accelerate the return of postoperative GI function…

    View Full Article
  5. CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET.

    Participating from the Palisade Bio management team will be Tom Hallam, Ph.D., Chief Executive Officer, Michael Dawson, M.D., Chief Medical Officer and Robert McRae, Senior Vice President, Operations and Strategic Development.

    Joining Palisade Bio management will be Key Opinion Leader, David B. Hoyt, MD, FACS, MAMSE. Dr. Hoyt is the Executive Director of the American College…

    View Full Article
View All Palisade Bio Inc. News